ERA

Download the full-sized PDF of Development of an ex vivo assay of hepatitis C specific T-cell responses using QuantiFERON®Download the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3PF0J

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Development of an ex vivo assay of hepatitis C specific T-cell responses using QuantiFERON® Open Access

Descriptions

Other title
Subject/Keyword
Quantiferon
T-cell response
Hepatitis C infection
Liver transplantation
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Asthana, Sonal
Supervisor and department
Kneteman, Norman (Surgery)
Humar, Atul (Medicine)
Examining committee member and department
Douglas, Donna (Surgery)
Mason, Andrew (Medicine)
Department
Department of Surgery
Specialization

Date accepted
2010-12-29T17:34:12Z
Graduation date
2011-06
Degree
Masters of Science
Degree level
Master's
Abstract
Cellular immune responses to Hepatitis C (HCV) epitopes are crucial for successful host response to HCV infection. We investigated a platform to assess specific and global immune responses in HCV infection. We identified 57 HCV peptides from literature (24 of CD4+, 33 of CD8+ specificity) and tested them in two peptide pools to assess specific response in non-transplanted and post-liver transplant (LT) patients. Robust interferon-gamma (IFN) response to CD4+ peptide and mitogen stimulation was seen in sustained virological clearance. IFN response to the CD4+ peptide pool could differentiate between SVR and NR with 82% accuracy. In patients with recurrent HCV post-LT, HCV-specific responses were attenuated, but global immune responses were preserved. Significantly lower specific (CD4+) and global immune responses (mitogen response) were observed in patients with advanced allograft disease (fibrosis score>2). Quantiferon-HCV may identify patients likely to respond to anti-HCV treatment, as well as post-LT patients with aggressive HCV recurrence.
Language
English
DOI
doi:10.7939/R3PF0J
Rights
License granted by Sonal Asthana (sasthana@ualberta.ca) on 2010-12-23T18:44:15Z (GMT): Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of the above terms. The author reserves all other publication and other rights in association with the copyright in the thesis, and except as herein provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-05-01T02:23:17.973+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 3215136
Last modified: 2015:10:12 16:59:52-06:00
Filename: Asthana_Sonal_Spring2011.pdf
Original checksum: e8a928ef2c2fe6ca9b8ce4b56b74d9ce
Well formed: true
Valid: true
Status message: File header gives version as 1.4, but catalog dictionary gives version as 1.3
File title: Microsoft Word - Asthana_Sonal_Winter2010.docx
File author: Sonal Asthana
Page count: 185
Activity of users you follow
User Activity Date